| Code | CSB-RA010949MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to bersanlimab, targeting intercellular adhesion molecule 1 (ICAM1), also known as CD54. ICAM1 is a cell surface glycoprotein that plays a critical role in immune cell trafficking and inflammation by mediating leukocyte adhesion and transmigration across the endothelium. This adhesion molecule is constitutively expressed at low levels on endothelial cells and leukocytes but becomes significantly upregulated during inflammatory responses. ICAM1 is implicated in various pathological conditions including autoimmune diseases, chronic inflammatory disorders, cancer metastasis, and transplant rejection, making it an important therapeutic target for immune modulation.
Bersanlimab is a clinical-stage humanized IgG1 monoclonal antibody designed to block ICAM1-mediated cellular interactions. This biosimilar provides researchers with a valuable tool for investigating ICAM1 biology, studying immune cell adhesion mechanisms, exploring inflammatory signaling pathways, and evaluating potential therapeutic strategies in oncology and immunology research. The antibody enables detailed examination of ICAM1's role in disease progression and immune regulation across multiple experimental models.
There are currently no reviews for this product.